Comparative Pharmacology
Head-to-head clinical analysis: ACTISITE versus OXY KESSO TETRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTISITE versus OXY KESSO TETRA.
ACTISITE vs OXY-KESSO-TETRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, though it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Oxycodone is combined with aspirin (OXY-KESSO-TETRA) for analgesic synergy.
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
200 mg orally every 8 hours for 10 days.
None Documented
None Documented
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
Terminal elimination half-life approximately 8-12 hours in adults with normal renal function; prolonged to 20-40 hours in moderate to severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
Primarily renal (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 20-30% is metabolized hepatically with metabolites excreted renally; less than 5% eliminated via bile/feces.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic